Lung cancer biomarker testing trial sees drop in deaths

Biomarker testing in individuals at risk of lung cancer led to a major reduction in deaths, new research reveals.

© National Cancer Institute/Unsplash

© National Cancer Institute/Unsplash

The University of St Andrews School of Medicine study, conducted with 12,000 smokers and ex-smokers, demonstrates how biomarkers - measurable indicators of biological changes - can identify individuals at high risk of lung cancer, leading to earlier detection and significantly improved outcomes.

The study, published in PLoS ONE, found that testing high-risk individuals with biomarkers led to a 40% reduction in deaths from lung cancer and other causes over five years.

The research team aims to explore how biomarker testing could enhance lung cancer screening programs currently being developed or implemented in several countries. This targeted strategy could improve the identification of individuals most at risk, ensuring that screening resources are used efficiently and effectively.

Dr Frank Sullivan, professor of primary care medicine at the University of St Andrews School of Medicine, said: ‘This study, along with others using imaging techniques, shows that earlier diagnosis of lung cancer is now possible. That is good news because, if caught early enough, the improved treatments now available have a much higher chance of success.'

Government pledges to lift half a million children out of poverty

Government pledges to lift half a million children out of poverty

By Lee Peart 05 December 2025

The Government has pledged to lift half a million children out of poverty by 2030.

Draft recommendations on prostate cancer screening issued

By Liz Wells 01 December 2025

The UK National Screening Committee, the expert group which advises the government and the NHS on screening, has issued draft recommendations about prostate ...

World-first platform determines whether AI algorithms are fit for NHS use

By Liz Wells 25 November 2025

Researchers from across London have developed the first real-world head-to-head testing platform to determine whether commercial AI algorithms are fit for NH...


Popular articles by Liz Wells